Skip to main content
. Author manuscript; available in PMC: 2024 Dec 3.
Published in final edited form as: Lancet. 2021 Jun 4;398(10299):491–502. doi: 10.1016/S0140-6736(21)01222-8

Table 2.

Overall complete remission/complete remission with incomplete hematologic recovery rate based on central assessment.

Response, n (%) All treated patients N=55
Overall CR/CRi 39 (70·9)*
 CR 31 (56·4)
 CRi 8 (14·5)
Blast-free hypoplastic or aplastic bone marrow 4 (7·3)
No response 9 (16·4)
Unknown or not evaluable 3 (5·5)
*

95% CI, 57–82 (p<0·0001).

The three patients who were unknown or not evaluable died (days 8, 15, and 18) prior to the first disease assessment.

CR=complete remission; CRi=complete remission with incomplete hematologic recovery.